Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BPMUF NASDAQ:RGC NASDAQ:VERA OTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$60.28$65.46$59.29▼$74.00$793.82M0.161 shsN/ARGCRegencell Bioscience$6.19-4.5%$22.65$5.80▼$69.00$3.20B1.66286,549 shs396,455 shsVERAVera Therapeutics$43.15+1.6%$36.06$19.07▼$56.05$3.10B0.931.22 million shs3.05 million shsZLDPFZealand Pharma A/S$42.11-1.8%$47.60$35.93▼$83.12$3.01B0.863,424 shs112 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%-7.41%-15.11%+4.46%RGCRegencell Bioscience0.00%-46.04%-72.89%-72.22%-62.76%VERAVera Therapeutics0.00%+21.00%+19.54%+11.44%+87.46%ZLDPFZealand Pharma A/S0.00%-4.16%-12.00%-4.07%-23.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$60.28$65.46$59.29▼$74.00$793.82M0.161 shsN/ARGCRegencell Bioscience$6.19-4.5%$22.65$5.80▼$69.00$3.20B1.66286,549 shs396,455 shsVERAVera Therapeutics$43.15+1.6%$36.06$19.07▼$56.05$3.10B0.931.22 million shs3.05 million shsZLDPFZealand Pharma A/S$42.11-1.8%$47.60$35.93▼$83.12$3.01B0.863,424 shs112 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%-7.41%-15.11%+4.46%RGCRegencell Bioscience0.00%-46.04%-72.89%-72.22%-62.76%VERAVera Therapeutics0.00%+21.00%+19.54%+11.44%+87.46%ZLDPFZealand Pharma A/S0.00%-4.16%-12.00%-4.07%-23.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea Pharmaceutica 2.00HoldN/AN/ARGCRegencell Bioscience 1.00SellN/AN/AVERAVera Therapeutics 2.75Moderate Buy$78.0080.76% UpsideZLDPFZealand Pharma A/S 2.60Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest BPMUF, RGC, ZLDPF, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026RGCRegencell Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026ZLDPFZealand Pharma A/S Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/11/2026ZLDPFZealand Pharma A/S Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/4/2026ZLDPFZealand Pharma A/S Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/2/2026VERAVera Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.006/2/2026VERAVera Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026VERAVera Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/2/2026VERAVera Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026VERAVera Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$91.004/20/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$280.43M2.83$3.85 per share15.66$11.73 per share5.14RGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/AZLDPFZealand Pharma A/S$1.40B2.16$13.58 per share3.10$31.61 per share1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$48.57MN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/AVERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)ZLDPFZealand Pharma A/S$977.29M$13.483.1220.25N/A68.82%41.80%38.49%8/13/2026 (Estimated)Latest BPMUF, RGC, ZLDPF, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/7/2026Q1 2026ZLDPFZealand Pharma A/S-$1.3652-$0.87+$0.4952-$0.87$2.81 million$5.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea Pharmaceutica0.595.114.68RGCRegencell BioscienceN/A1.41N/AVERAVera Therapeutics0.1513.6413.64ZLDPFZealand Pharma A/S0.0237.1737.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ARGCRegencell Bioscience0.13%VERAVera Therapeutics99.21%ZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ARGCRegencell BioscienceN/AVERAVera Therapeutics15.90%ZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableRGCRegencell Bioscience10494.49 millionN/AN/AVERAVera Therapeutics4071.78 million60.37 millionOptionableZLDPFZealand Pharma A/S34071.53 millionN/ANot OptionableBPMUF, RGC, ZLDPF, and VERA HeadlinesRecent News About These CompaniesZealand Pharma - Transactions related to share buy-back program (week 26, 2026)2 hours ago | markets.businessinsider.comZealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Down 63.8% in JuneJune 28 at 1:40 AM | americanbankingnews.comZealand Pharma - Transactions related to share buy-back program (week 25, 2026)June 22, 2026 | markets.businessinsider.comZealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 21, 2026 | americanbankingnews.comZealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmakerJune 19, 2026 | cnbc.comZealand Pharma - Transactions related to share buy-back program (week 24, 2026)June 15, 2026 | markets.businessinsider.comDrugmakers race to find a place in the next wave of obesity drugsJune 13, 2026 | cnbc.comRoche and Zealand Advance Combo Obesity Drug Trial, Signaling New Momentum for ZLDPFJune 12, 2026 | tipranks.comZealand Pharma - Transactions related to share buy-back program (week 23, 2026)June 8, 2026 | markets.businessinsider.comZealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side EffectsJune 8, 2026 | wsj.comZealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trialJune 8, 2026 | marketwatch.comZealand Pharma shares drop 20% as obesity drug side effects raise concernsJune 8, 2026 | reuters.comZealand Pharma to participate in the Goldman Sachs Global Healthcare ConferenceJune 2, 2026 | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (week 22, 2026)June 2, 2026 | markets.businessinsider.comZealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific SessionsMay 27, 2026 | markets.businessinsider.comResolutions from Zealand Pharma's Extraordinary General Meeting 2026May 26, 2026 | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (week 21, 2026)May 26, 2026 | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)May 14, 2026 | markets.businessinsider.comIs Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?May 12, 2026 | zacks.comZealand Pharma - Execution framework for share buy-back programMay 7, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026BPMUF, RGC, ZLDPF, and VERA Company DescriptionsBasilea Pharmaceutica OTCMKTS:BPMUF$60.28 0.00 (0.00%) As of 06/26/2026Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Regencell Bioscience NASDAQ:RGC$6.19 -0.29 (-4.48%) Closing price 04:00 PM EasternExtended Trading$6.38 +0.19 (+3.15%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Vera Therapeutics NASDAQ:VERA$43.15 +0.69 (+1.63%) Closing price 04:00 PM EasternExtended Trading$43.52 +0.37 (+0.85%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Zealand Pharma A/S OTCMKTS:ZLDPF$42.11 -0.78 (-1.82%) As of 09:30 AM EasternZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
